Table 1.
Demographic and clinical characteristics (N=141)
| Overall n=141 |
Control n=70 |
Weight-lifting n=71 |
Pa | |
|---|---|---|---|---|
| Age, Yr, Mean±SD | 57±10 | 58±10 | 56±9 | 0.56 |
| Race, n(%) | 0.87 | |||
| Black | 54 (38%) | 26 (37%) | 28 (39%) | |
| White | 82 (58%) | 42 (60%) | 40 (56%) | |
| Other | 5 (4%) | 2 (3%) | 3 (4%) | |
| Education, n(%) | 0.56 | |||
| High school or less | 29 (21%) | 16 (23%) | 13 (18%) | |
| Some college | 50 (35%) | 24 (34%) | 26 (37%) | |
| College degree or more | 62 (44%) | 30 (43%) | 32 (45%) | |
| BMI, kg/m2, Mean±SD | 30.5±6.4 | 29.9±6.6 | 31.0±6.2 | 0.33 |
| BMI category, n(%) | 0.59 | |||
| Normal weight (<25kg/m2) | 30 (21%) | 17 (24%) | 13 (18%) | |
| Overweight (25–30kg/m2) | 41 (29%) | 21 (30%) | 20 (28%) | |
| Obese (>30kg/m2) | 70 (50%) | 32 (46%) | 38 (54%) | |
| Month since diagnosis, Mean±SD | 83±45 | 88±45 | 79±45 | 0.23 |
| Month since lymphedema diagnosis, Mean±SD | 61±45 | 61±45 | 61±45 | 0.95 |
| Month since last lymphedema treatment, Mean±SD | 36±36 | 36±37 | 36±35 | 0.92 |
| Interlimb volume % difference, Mean±SD | 16.1±15.2 | 17.3±16.6 | 15.0±14.7 | 0.49 |
| Interlimb volume % difference stage, n(%) | 0.48 | |||
| Stage 0 (<5%) | 30 (21%) | 16 (23%) | 14 (20%) | |
| Stage I (5-<10%) | 22 (16%) | 10 (14%) | 12 (17%) | |
| Stage II (10-<30%) | 63 (45%) | 28 (40%) | 35 (49%) | |
| Stage III (>30%) | 26 (18%) | 16 (23%) | 10 (14%) | |
| Common toxicity criteria lymphedema grade, n(%) | 0.25 | |||
| 0 | 12 (8%) | 7 (10%) | 5 (7%) | |
| 1 | 30 (21%) | 12 (17%) | 18 (25%) | |
| 2 | 58 (41%) | 26 (37%) | 32 (45%) | |
| 3 | 41 (29%) | 25 (36%) | 16 (22%) | |
| Breast cancer stage, n(%) | 0.19 | |||
| 1 | 57 (40%) | 24 (34%) | 33 (4 6%) | |
| 2 | 1 (1.0%) | 0 | 1 (1%) | |
| 3 | 44 (31%) | 22 (31%) | 22 (31%) | |
| Unknown | 39 (28%) | 24 (34%) | 15 (21%) | |
| Treatment, n(%) | ||||
| Radiation | 112 (79%) | 53 (76%) | 59 (83%) | 0.30 |
| Chemotherapy | 115 (82%) | 56 (80%) | 59 (83%) | 0.67 |
| Tamoxifen | 17 (12.2) | 3 (4%) | 14 (20%) | <0.01 |
| Aromatase Inhibitor | 1 (1%) | 1 (1%) | 0 (0%) | 0.31 |
| Breast cancer in dominant side, n (%) | 72 (51%) | 35 (50%) | 37 (52%) | 0.87 |
a
two-sided t-test or chi-square test